Horse Allo 20
allogeneic equine adipose-derived mesenchymal stem cells
Table of contents
Refused
This medicine was refused authorisation for use in the European Union.
Overview
On 21 June 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Horse Allo 20, intended for the treatment of lameness in adult horses with osteoarthritis.
On 24 January 2019, the CVMP revised part of its opinion but confirmed its recommendation to refuse the marketing authorisation.
The company that applied for authorisation is Centauri Biotech SL.
This EPAR was last updated on 12/09/2019
Application details
Product details | |
---|---|
Name |
Horse Allo 20
|
Active substance |
allogeneic equine adipose-derived mesenchymal stem cells
|
International non-proprietary name (INN) or common name |
allogeneic equine adipose-derived mesenchymal stem cells
|
Species |
Horses
|
Application details | |
---|---|
Marketing-authorisation applicant |
Centauri Biotech SL
|
Date of opinion |
21/06/2018
|
Date of refusal of marketing authorisation |
13/05/2019
|